Audeo Oncology sets terms for $49 million IPO


Shutterstock photo

Audeo Oncology, which utilizes Hyaluronic Acid Chemotransport Technology to increase the effectiveness of anti-cancer drugs, announced terms for its IPO on Thursday. The San Francisco, CA-based company plans to raise $49 million by offering 3.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Audeo Oncology would command a fully diluted market value of $163 million. Audeo Oncology, which was founded in 2006 and did not record revenue for the 12 months ended 9/30/2012, plans to list on the NASDAQ under the symbol AURX. Leerink Swann and Oppenheimer & Co. are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by